Capcom (OTCMKTS: CCOEY) and Omnicell Technologies (NASDAQ:OMCL) are both consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Institutional and Insider Ownership
0.0% of Capcom shares are owned by institutional investors. 3.7% of Omnicell Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Capcom pays an annual dividend of $0.04 per share and has a dividend yield of 0.4%. Omnicell Technologies does not pay a dividend. Capcom pays out 22.2% of its earnings in the form of a dividend.
Valuation & Earnings
This table compares Capcom and Omnicell Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Capcom||$806.32 million||2.96||$79.27 million||$0.18||60.56|
|Omnicell Technologies||$716.16 million||2.45||$20.60 million||$0.18||251.22|
Capcom has higher revenue and earnings than Omnicell Technologies. Capcom is trading at a lower price-to-earnings ratio than Omnicell Technologies, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for Capcom and Omnicell Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Capcom currently has a consensus price target of $17.84, suggesting a potential upside of 63.67%. Omnicell Technologies has a consensus price target of $56.14, suggesting a potential upside of 24.35%. Given Capcom’s higher possible upside, research analysts clearly believe Capcom is more favorable than Omnicell Technologies.
This table compares Capcom and Omnicell Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Capcom has a beta of -5.34, meaning that its stock price is 634% less volatile than the S&P 500. Comparatively, Omnicell Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
Omnicell Technologies beats Capcom on 9 of the 15 factors compared between the two stocks.
Capcom Company Profile
Capcom Co., Ltd. plans, develops, manufactures, sells, and distributes home video games, online games, mobile games, and arcade games in Japan and internationally. It operates through Digital Contents, Arcade Operations, Amusement Equipments, and Other Businesses segments. The Digital Contents segment develops and sells package games and digital download content. This segment also develops and manages mobile contents and PC online games. The Arcade Operations segment operates ?Plaza Capcom? amusement facilities primarily in commercial complexes, and hosts various events. The Amusement Equipments segment is involved in the development, manufacture, and sale of frames and LCD devices for gaming machines, as well as software; and development, production, and sale of arcade games for amusement facilities. The Other Businesses segment publishes walkthrough and strategy guides, as well as game art books; licenses music CDs and merchandise; and develops game content into movies and animated television programs. The company was founded in 1979 and is headquartered in Osaka, Japan.
Omnicell Technologies Company Profile
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Receive News & Ratings for Capcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capcom and related companies with MarketBeat.com's FREE daily email newsletter.